Key result
Mexiletine completely suppresses refractory TdP and VF and shortens QTc in a congenital LQTS2 patient.
Why the study?
Does mexiletine prevent refractory Torsade de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome?
Case Report (n=1)
Does mexiletine prevent refractory Torsade de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome?
Mexiletine may be an effective therapy for suppressing refractory Torsade de Pointes and ventricular fibrillation in patients with congenital type 2 long QT syndrome.
May support mexiletine in refractory TdP with type 2 LQTS; leaves open confirmation in prospective studies.
We report a 28-year-old female patient with congenital type 2 long QT syndrome (LQTS) in which mexiletine shortened corrected QT interval (QTc) and effectively prevented refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF). She developed TdP and VF, and was subsequently diagnosed with congenital type 2 LQTS. She had refractory TdP and VF every day despite medical therapy including β-blocker. They were completely suppressed after the initiation of mexiletine with shorting of QTc interval.
No takes yet. Share an insight, caveat, or question.
Nakashima et al. (2022) conducted a case report in Congenital type 2 long QT syndrome (LQTS) (n=1). Mexiletine was evaluated on Suppression of refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF) and shortening of QTc interval. Mexiletine completely suppressed refractory Torsade de Pointes and ventricular fibrillation and shortened the QTc interval in a 28-year-old female with congenital type 2 long QT syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: